Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study

Journal of Hepatology

Volumn 37, Issue 6, 2002, Pages 717-722

  Terg, Rubén ^a   Coronel, Emma ^a   Sordá, Juan ^b   Muñoz, Alberto E ^a   Findor, Jorge ^b  

^a UNIVERSIDAD DEL SALVADOR   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Cholestasis; Naltrexone; Pruritus

Indexed keywords

COLESTYRAMINE; CORTICOSTEROID; NALTREXONE; ONDANSETRON; PHENOBARBITAL; PLACEBO; REVEZ; RIFAMPICIN; URSODEOXYCHOLIC ACID; NARCOTIC ANTAGONIST;

ABDOMINAL CRAMP; ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUSHING; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; LIVER FUNCTION; MALE; NAUSEA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA; TREMOR; VERTIGO; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA; DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PATHOPHYSIOLOGY; SAFETY;

ADMINISTRATION, ORAL; ADULT; AGED; CHOLESTASIS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT; PRURITUS; SAFETY;

EID: 0036893023     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00318-5     Document Type: Article

References (41)

1. Bergasa NV, Jones EA. The pruritus of cholestasis. Semin Liver Dis 1993;13:319-327.
2. Heathcote J. Management of primary biliary cirrhosis. Hepatology 2000;32:1005-1013.
3. Khandelwal M, Malet PF. Pruritus associated with cholestasis: A review of pathogenesis and management. Dig Dis Sci 1994;39:1-8.
4. Datta D, Sherlock S. Cholestyramine for long-term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 1966;50:323-332.
5. Heuman DM. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology 1993;104:1865-1868.
6. Poupon RE, Poupon R, Balkau B. UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994;330:342-347.
7. Combes B, Carithers RL, Maddrey W, Lin D, McDonald M, Wheeler D, et al. A randomized double-blind placebo controlled trial of Ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995;22:759-766.
8. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind crossover randomized trial. Gastroenterology 1988;94:488-493.
9. Bachs L, Parés A, Elena M, Piera C, Rodés J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989;1:574-576.
10. Cynamon HA, Andrés JM, Iafrate RP. Rifampin relieves pruritus in children with cholestasis liver disease. Gastroenterology 1990;98:1013-1016.
11. Podestá A, López P, Terg R, Villamil F, Flores D, Mastai R, Udaondo C, et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991;36:216-220.
12. Bachs L, Parés A, Elena M, Piera C, Rodés J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992;102:2077-2080.
13. Cohen LB, Ambinder EP, Wolke AM, Field S, Schaffner F. Role of plasmapheresis in primary biliary cirrhosis. Gut 1985;26:291-294.
14. Markus BH, Dickson ER, Grambsch PM, Fleming T, Mazzaferro V, Wiesner R, Van Thiel D. Efficacy of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 1989;320:1709-1713.
15. Weisner R, Porayko M, Dickson R, Gores G, La Russo N, Hay J, Wahlstrom H. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 1992;16:1290-1299.
16. Murphy GM, Ross A, Billing BH. Serum bile acids in primary biliary cirrhosis. Gut 1972;13:201-206.
17. Ghent CN, Bloomer JR, Klatskin G. Elevations in skin tissue levels of bile acids in human cholestasis; relation to serum levels and to pruritus. Gastroenterology 1992;102:544-549.
18. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. Br Med J 1988;297:1501-1504.
19. Jones EA, Bergasa NV. The pruritus of cholestasis and the opioid system in Grand Rounds at the clinical center of the National Institutes of Health. J Am Med Assoc 1992;23:3359-3362.
20. Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology 1999;29:1003-1006.
21. Thornton JR, Losowsky MS. Plasma leucine enkephalin is increased in liver disease. Gut 1989;3:1392-1395.
22. Jones EA, Bergasa NV. The pruritus of cholestasis. From bile acids to opiate antagonists. Hepatology 1990;11:884-887.
23. Bergasa NV, Jones EA. Management of the pruritus of cholestasis: Potential role of opiate antagonists. Am J Gastroenterol 1991;86:1404-1412.
24. Bergasa NV, Thomas DA, Vergalla J, Turner ML, Jones EA. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci 1993;53:1253-1257.
25. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, Korenman JC. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992;102:544-549.
26. Bergasa NV, Alling DW, Talbot TL, Swaln MG, Yurdaydin C, Turner ML, Schmitt JM. Effects of naloxone infusions in patients with the pruritus of cholestasis. Ann Intern Med 1995;123:161-167.
27. Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, et al. Open label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998;27:679-684.
28. Jaffe H, Martin D. Opioid analgesics and antagonists. In: Gilman A, Goodman L, Rall T, Marad F, editors. The Pharmacologic Basis of Therapeutics, 7th Ed. New York: MacMillan, 1985. pp. 491-531.
29. Jones EA, Dekker LR. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 2000;118:431-432.
30. Shawcross D, Jalan R. Delayed opioid withdrawal-like reaction in primary biliary cirrhosis following naloxone therapy. Gastroenterology 2001;121:743-744.
31. Gonzalez JP, Brodgen RN. Naltrexone: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988;35:192-213.
32. Bertolotti M, Ferrari A, Vitale G, Stefani M, Trenti T, Loria P, et al. Effect of liver cirrhosis on the systemic availability of naltrexone in humans. J Hepatol 1997;27:505-511.
33. Carson KL, Tran TT, Cotton P, Sharara AI, Hunt CM. Pilot study of the use of Naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996;91:1022-1023.
34. Wolfhagen FHJ, Sternieri E, Hop WCJ, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: A double blind placebo-controlled study. Gastroenterology 1997:1264-1269.
35. O'Donohue JW, Haigh C, Williams R. Ondaseatron in the treatment of the pruritus of cholestasis: A randomised controlled trial. Gastroenterology 1997;112:A1349.
36. McCormack H, Horne D, Sheather S. Clinical applications of visual analogue scales: A critical review. Psychol Med 1988;18:1007-1019.
37. Pauli-Magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, et al. Naltrexone does not relieve uremic pruritus: Results of a randomized, double blind, placebo-controlled crossover study. J Am Soc Nephrol 2000;11:514-519.
38. Sax DS, Kornetsky C, Kim A. Lack of hepatotoxicity with naltrexone treatment. J Clin Pharmacol 1994;34:898-901.
39. Mitchell JE. Naltrexone and hepatotoxicity. Lancet 1986;i:1215.
40. Jones EA, Bergasa NV. The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Eur J Gastroenterol Hepatol 1999;11:623-631.
41. Terra SG, Tsunoda SM. Opioid antagonists in the treatment of pruritus from cholestatic liver disease. Ann Pharmacother 1998;32:1228-1230.